Earlier this month, we co-hosted the Psychedelic Healthcare Forum in New York City. There, several sessions featured conversations related to psychedelic drug development, which we recap here. The three sessions covered in this article were: Drug development is notoriously capital intensive, and the types of investors that have funded psychedelic candidates have changed dramatically over…
